283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial

Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy, S-B. Kim, Steven J. Isakoff, C.H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Lian, S-J. Reilly, Heather Hinton, Matthew Wongchenko, Aruna Mani, Mafalda Oliveira